Butterfly Network Inc Stock Price, News & Analysis

Butterfly Network (NYSE:BFLY) announced the publication of significant clinical trial results in JAMA demonstrating the effectiveness of their POCUS (Point-of-Care Ultrasound) program. The POCUS-CARE trial, conducted at Rutgers Robert Wood Johnson Medical School, showed that implementing Butterfly's ultrasound technology with AI assistance led to substantial improvements in hospital efficiency.

The study of 208 patients revealed that the POCUS program resulted in 246 hospital bed-days saved and $751,537 in direct cost savings. The POCUS group demonstrated a 30% reduction in expected hospital length of stay (8.3 vs. 11.9 days), with the technology changing clinical management in 35% of cases. The program focused particularly on lung ultrasound for pulmonary congestion assessment, supported by Butterfly's FDA-cleared Auto B-line Counter.

Butterfly Network (NYSE:BFLY) has announced a strategic distribution agreement with Clipper Distributing to commercialize its point-of-care ultrasound devices in the veterinary market. The partnership will focus on distributing the Butterfly iQ+ Vet, the world's only handheld, single-probe, whole-body, multi-species imaging system.

The collaboration leverages Butterfly's proprietary Ultrasound-on-Chip™ technology and Butterfly Cloud workflow management software, combined with Clipper's extensive distribution network in the veterinary health market. The second and third generation probes feature enhanced imaging capabilities, procedural guidance tools, and improved usability features designed specifically for veterinary applications.

Butterfly Network (NYSE:BFLY) has joined the CAD LUS4TB consortium to evaluate AI-assisted point-of-care ultrasound (POCUS) for tuberculosis detection in Sub-Saharan Africa. The project, funded with €10 million from the EU's Global Health EDCTP3, will trial a new AI algorithm using Butterfly's software development platform and portable ultrasound devices.

The study, launching in September, will involve 3,000 adult patients and aims to enable non-radiologist healthcare workers to detect TB using AI-led POCUS. This initiative addresses a critical need in Africa, where 2.5 million people contracted TB in 2022, representing 25% of global cases and over 33% of TB deaths.

Butterfly Network (NYSE:BFLY) announced significant advances in AI-powered aortic screening technology. A new study from Tufts Medical Center, published in European Heart Journal, demonstrated that their machine learning model achieved a 0.94 AUROC accuracy in identifying aortic stenosis using Butterfly iQ+ handheld ultrasound devices.

The company also launched a new Aorta Exam Protocol on their Butterfly ScanLab™ AI-powered education app, designed to train users in scanning abdominal aorta and recognizing normal anatomy. This development aims to improve detection of conditions like abdominal aortic aneurysms and dissections.

The innovations target aortic stenosis, which affects over 13% of Americans aged 75+ and often remains undiagnosed until advanced stages, particularly in underserved populations.

Butterfly Network (NYSE:BFLY) reported its strongest quarterly performance in Q2 2025, with revenue reaching $23.4 million, up 9% year-over-year. The company achieved record gross margins of 64% and reduced quarterly cash burn to $7.1 million.

Key highlights include international revenue growth of 19% to $6.2 million, driven by the iQ3 launch. The company announced upcoming launch of Compass AI software in Q3 and reported progress in Butterfly HomeCare pilot program. Additionally, CFO Heather Getz resigned, with CAO Megan Carlson assuming interim financial leadership.

Butterfly revised its FY2025 guidance to $92-96 million in revenue (15% growth) and improved Adjusted EBITDA loss guidance to $32-37 million.

Butterfly Network (NYSE:BFLY) reported strong Q2 2025 financial results, achieving its highest quarterly revenue of $23.4 million, representing 9% year-over-year growth. The company reached record gross margins of 64% and reduced quarterly cash burn to a historic low of $7.1 million.

Key highlights include U.S. revenue of $17.2 million and international revenue growth of 19% to $6.2 million. The company revised its full-year 2025 guidance to revenue of $91-95 million (13% growth) and improved Adjusted EBITDA loss guidance to $32-37 million.

Additionally, BFLY announced the resignation of CFO Heather Getz, with Chief Accounting Officer Megan Carlson assuming interim financial leadership roles. The company is preparing to launch its next-generation Compass AI software platform in Q3 and advancing its Butterfly HomeCare solution.

Butterfly Network (NYSE:BFLY), a digital health company specializing in portable ultrasound technology, will report its second quarter 2025 financial results on August 1, 2025, before market opens.

The company will host a conference call and webcast at 8:00 AM ET on the same day, featuring CEO Joseph DeVivo and CFO Heather Getz to discuss financial performance and operational progress. The call will be available via webcast and telephone, with replay access until August 15, 2025.

Butterfly Network (NYSE: BFLY) announces progress in their request to revoke a lead exemption under the EU's RoHS Directive for ultrasound transducers. The European Commission has appointed Oeko-Institut to evaluate the Company's October 2024 submission to remove Annex IV n. 14, which allows lead in piezoelectric materials. The stakeholder consultation period runs from June 6 to August 1, 2025, with Oeko-Institut's recommendation expected by Q2 2026. If approved, implementation would take 12-18 months after the final Delegated Act. This initiative aligns with EU's sustainability goals and aims to modernize medical imaging standards.

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's President, CEO, and Chairman, Joseph DeVivo, will deliver a presentation on June 5, 2025, at 8:00 am CT in Chicago. The presentation will be accessible via live webcast in the Events & Presentations section of Butterfly's investor website, with a replay option available afterward. Investors can arrange one-on-one meetings with Mr. DeVivo through their William Blair representatives.